Juan Francisco R. M.
- Country
- Spain
- Department
- Oncology
Research Overview
- Evaluation of Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Patients with Metastatic Castration-Resistant Prostate Cancer
- A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
- Phase 1 Open-Label Dose Escalation and Expansion Study of SNV1521 in Patients with Advanced Solid Tumors
Data & Insights
Has run more than one trial at 237 of 477 partner sites.
Specializations
Melanoma Research
The investigator specializes in treating advanced melanoma, with particular focus on unresectable and metastatic cases. Their research encompasses novel therapeutic approaches including tumor-infiltrating lymphocytes and innovative combination therapies.
- Advanced Stage Melanoma Treatment
- Immunotherapy Combinations
- Post-surgical Therapy
Prostate Cancer Studies
Demonstrates significant expertise in treating metastatic castration-resistant prostate cancer. The research portfolio includes evaluation of novel hormonal therapies and investigation of biochemically recurrent prostate cancer.
- Hormonal Therapy Innovations
- Metastatic Disease Management
- Oligometastatic Treatment Approaches
Therapeutic Innovation
Focuses on developing combination treatment strategies and evaluating novel therapeutic agents. Research includes investigation of biosimilar therapies and innovative drug delivery methods.
- Novel Drug Development
- Combination Therapy Assessment
- Treatment Response Evaluation
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.